Table 1.
The demographics, clinical characteristics and outcomes of patients referred for IMH evaluation
| Total | |
|---|---|
| Age (years) | 60 (10) |
| Gender (female) | 13 (62%) |
| Race | |
| Asian | 1 (5%) |
| Black or African American | 4 (19%) |
| Hispanic | 1 (5%) |
| White or Caucasian | 15 (71%) |
| History of autoimmune disease | 1 (5%) |
| BMI at referral | 28 (24–31) |
| Tumor type | |
| Bladder | 2 (10%) |
| Breast | 4 (19%) |
| Esophageal | 2 (10%) |
| GBM | 2 (10%) |
| Gastric | 2 (10%) |
| Liposarcoma | 1 (5%) |
| Melanoma | 3 (14%) |
| NSCLC | 3 (14%) |
| Ovarian | 1 (5%) |
| Pancreatic | 1 (5%) |
| Metastatic | 7 (33%) |
| Type of immunotherapy | |
| CTLA-4 | 2 (10%) |
| CTLA-4 PD-1/PD-L1 | 3 (14%) |
| PD-1/PD-L1 | 16 (76%) |
| ANA titer (> 1:80) | 6 (35%) |
| ASMA titer (> 1:40) | 2 (13%) |
| Doses of ICI before IMH | 3 (2–7) |
| Time from first ICI to IMH referral (days) | 84 (44–200) |
| Toxicity at referral | |
| Grade 1–2 | 6 (29%) |
| Grade 3–4 | 15 (71%) |
| Pattern of injury | |
| Hepatocellular | 7 (33%) |
| Mixed | 6 (29%) |
| Cholestatic | 8 (38%) |
| Toxicity at peak | |
| Grade 1–2 | 5 (24%) |
| Grade 3–4 | 16 (76%) |
| Pattern of injury | |
| Hepatocellular | 6 (29%) |
| Mixed | 8 (38%) |
| Cholestatic | 7 (33%) |
| Toxicity 1 week after treatment | |
| Grade 1–2 | 7 (44%) |
| Grade 3–4 | 9 (56%) |
| Treatment with steroid | 17 (81%) |
| Initial dosing of steroids > 1 mg/kg/day prednisone equivalent | 9 (53%) |
| Duration of steroid (days) | 58 (14–111) |
| Time from referral to death (days) | 51 (11–412) |
| Time from referral to resolution (days) | 111 (41–214) |
| Death at follow-up | 14 (67%) |
n (%), mean (STD), median (IQR)